EP3383914A4 - ANTI-OX40 ANTIBODIES AND METHODS OF USE - Google Patents
ANTI-OX40 ANTIBODIES AND METHODS OF USE Download PDFInfo
- Publication number
- EP3383914A4 EP3383914A4 EP16871651.2A EP16871651A EP3383914A4 EP 3383914 A4 EP3383914 A4 EP 3383914A4 EP 16871651 A EP16871651 A EP 16871651A EP 3383914 A4 EP3383914 A4 EP 3383914A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibodies
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562262371P | 2015-12-02 | 2015-12-02 | |
| PCT/US2016/064794 WO2017096281A1 (en) | 2015-12-02 | 2016-12-02 | Anti-ox40 antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3383914A1 EP3383914A1 (en) | 2018-10-10 |
| EP3383914A4 true EP3383914A4 (en) | 2019-10-30 |
Family
ID=58797926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP16871651.2A Withdrawn EP3383914A4 (en) | 2015-12-02 | 2016-12-02 | ANTI-OX40 ANTIBODIES AND METHODS OF USE |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3383914A4 (en) |
| MA (1) | MA43389A (en) |
| WO (1) | WO2017096281A1 (en) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI716405B (en) | 2015-05-07 | 2021-01-21 | 美商艾吉納斯公司 | Anti-ox40 antibodies and methods of use thereof |
| EP3383430A4 (en) | 2015-12-02 | 2019-12-18 | Agenus Inc. | ANTIBODIES AND THEIR METHODS OF USE |
| WO2018089628A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| CR20190330A (en) | 2016-12-15 | 2019-12-19 | Abbvie Biotherapeutics Inc | Anti-ox40 antibodies and their uses |
| KR20200074214A (en) | 2017-11-01 | 2020-06-24 | 브리스톨-마이어스 스큅 컴퍼니 | Anti-stimulatory antibody for use in treating cancer |
| PE20210665A1 (en) | 2018-03-23 | 2021-03-31 | Bristol Myers Squibb Co | ANTIBODIES AGAINST MICA AND / OR MICB AND ITS USES |
| JP7611700B2 (en) | 2018-03-27 | 2025-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Real-time titer monitoring using UV signal |
| CA3103040A1 (en) * | 2018-05-11 | 2019-11-14 | Wuxi Biologics (Shanghai) Co., Ltd. | Fully human antibodies against ox40, method for preparing same, and use thereof |
| SG11202012043RA (en) | 2018-07-03 | 2021-01-28 | Gilead Sciences Inc | Antibodies that target hiv gp120 and methods of use |
| WO2020014583A1 (en) | 2018-07-13 | 2020-01-16 | Bristol-Myers Squibb Company | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor |
| EP4559485A3 (en) | 2018-07-19 | 2025-08-06 | Ichnos Sciences S.A. | Liquid antibody formulation |
| JP7709376B2 (en) * | 2018-10-23 | 2025-07-16 | ブイオーアール バイオファーマ インコーポレーテッド | Fc-silenced antibody drug conjugates (ADCs) and uses thereof |
| WO2020142626A1 (en) * | 2019-01-04 | 2020-07-09 | Gigagen, Inc. | Anti-ox40 binding proteins and methods of use thereof |
| US20220135619A1 (en) | 2019-02-24 | 2022-05-05 | Bristol-Myers Squibb Company | Methods of isolating a protein |
| SI3938047T1 (en) | 2019-03-22 | 2022-10-28 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| TW202231277A (en) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies |
| US20220220430A1 (en) | 2019-05-23 | 2022-07-14 | Bristol-Myers Squibb Company | Methods of monitoring cell culture media |
| CN114174538A (en) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | Multiple tumor gene signatures suitable for immunooncology therapy |
| EP3977132A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| KR20220016155A (en) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | Methods of Identifying Suitable Subjects for Immuno-Oncology (I-O) Therapy |
| JP7295283B2 (en) | 2019-06-25 | 2023-06-20 | ギリアード サイエンシーズ， インコーポレイテッド | FLT3L-FC fusion proteins and methods of use |
| JP7454645B2 (en) | 2019-07-16 | 2024-03-22 | ギリアード サイエンシーズ， インコーポレイテッド | HIV vaccine and its production and use methods |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| HRP20241379T1 (en) | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | HBV VACCINES AND HBV TREATMENT PROCEDURES |
| EP4045083B1 (en) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| TWI778443B (en) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1 inhibitors |
| ES3022990T3 (en) | 2019-12-06 | 2025-05-29 | Prec Biosciences Inc | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| CN117736207A (en) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | Diacylglycerol kinase modulating compounds |
| TWI832035B (en) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| TWI845826B (en) | 2020-03-20 | 2024-06-21 | 美商基利科學股份有限公司 | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| MX2022013619A (en) | 2020-05-01 | 2022-11-16 | Gilead Sciences Inc | 2,4-DIOXOPYRIMIDINE COMPOUNDS THAT INHIBIT CD73. |
| EP4153181A1 (en) | 2020-05-21 | 2023-03-29 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| MX2023001507A (en) | 2020-08-07 | 2023-03-06 | Gilead Sciences Inc | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use. |
| CN114106173A (en) * | 2020-08-26 | 2022-03-01 | 上海泰槿生物技术有限公司 | anti-OX 40 antibodies, pharmaceutical compositions and uses thereof |
| CA3190660A1 (en) | 2020-08-31 | 2022-03-03 | George C. Lee | Cell localization signature and immunotherapy |
| JP2023544410A (en) | 2020-10-05 | 2023-10-23 | ブリストル－マイヤーズ スクイブ カンパニー | Methods for concentrating proteins |
| TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
| US20220144923A1 (en) | 2020-11-11 | 2022-05-12 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| CA3196999A1 (en) | 2020-12-28 | 2022-07-07 | Masano HUANG | Methods of treating tumors |
| SMT202500208T1 (en) | 2020-12-28 | 2025-07-22 | Bristol Myers Squibb Co | Antibody compositions and methods of use thereof |
| AU2021414400A1 (en) | 2020-12-31 | 2023-08-17 | Innate Pharma | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| TW202302145A (en) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer |
| TW202348237A (en) | 2021-05-13 | 2023-12-16 | 美商基利科學股份有限公司 | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| CN117480155A (en) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | Diacylglycerol kinase modulating compounds |
| CN117377671A (en) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | Diacylglycerol kinase modulating compounds |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686091B2 (en) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | Diacylglycerol kinase modulating compounds |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (en) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | CD73 compound |
| FI4445900T3 (en) | 2021-12-03 | 2025-08-05 | Gilead Sciences Inc | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION |
| CN118355020A (en) | 2021-12-03 | 2024-07-16 | 吉利德科学公司 | Therapeutic compounds for HIV infection |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (en) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7 inhibitors |
| WO2023173011A1 (en) | 2022-03-09 | 2023-09-14 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
| TW202346277A (en) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros zinc finger family degraders and uses thereof |
| KR20240159621A (en) | 2022-03-18 | 2024-11-05 | 브리스톨-마이어스 스큅 컴퍼니 | Method for isolating a polypeptide |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (en) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | Combination therapy for treating colorectal cancer |
| TWI856796B (en) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| PE20250157A1 (en) | 2022-04-21 | 2025-01-22 | Gilead Sciences Inc | KRAS G12D MODULATION COMPOUNDS |
| AU2023274452A1 (en) | 2022-05-27 | 2025-01-16 | Innate Pharma | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| CN119384415A (en) | 2022-07-01 | 2025-01-28 | 吉利德科学公司 | CD73 compounds |
| EP4547659A1 (en) | 2022-07-01 | 2025-05-07 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| EP4554628A1 (en) | 2022-07-12 | 2025-05-21 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| CA3265134A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| EP4583999A1 (en) | 2022-09-09 | 2025-07-16 | Bristol-Myers Squibb Company | Methods of separating chelator |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| KR20250167002A (en) | 2023-04-11 | 2025-11-28 | 길리애드 사이언시즈, 인코포레이티드 | KRAS modulating compounds |
| AU2024259111A1 (en) | 2023-04-19 | 2025-10-16 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| CN121079300A (en) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | PRMT5 inhibitors and their uses |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| US20250011352A1 (en) | 2023-05-31 | 2025-01-09 | Gilead Sciences, Inc. | Solid forms |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250127801A1 (en) | 2023-10-11 | 2025-04-24 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025080863A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025137245A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
| WO2025184609A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025184452A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025184447A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| CA2695309A1 (en) * | 2007-09-07 | 2009-03-12 | Symphogen A/S | Methods for recombinant manufacturing of anti-rsv antibodies |
| CA2742968C (en) * | 2008-11-07 | 2020-06-09 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| US9150663B2 (en) * | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| EA031849B1 (en) * | 2010-08-23 | 2019-03-29 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Anti-ox40 antibodies and methods of using the same |
| AU2014364606A1 (en) * | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
-
2016
- 2016-12-02 MA MA043389A patent/MA43389A/en unknown
- 2016-12-02 EP EP16871651.2A patent/EP3383914A4/en not_active Withdrawn
- 2016-12-02 WO PCT/US2016/064794 patent/WO2017096281A1/en not_active Ceased
Non-Patent Citations (4)
| Title |
|---|
| B. D. CURTI ET AL: "OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients", CANCER RESEARCH, vol. 73, no. 24, 31 October 2013 (2013-10-31), pages 7189 - 7198, XP055194254, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-12-4174 * |
| MAHRUKH HUSENI ET AL: "Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 2, no. Suppl 3, 6 November 2014 (2014-11-06), pages P253, XP021202522, ISSN: 2051-1426, DOI: 10.1186/2051-1426-2-S3-P253 * |
| See also references of WO2017096281A1 * |
| STEFANIE N. LINCH ET AL: "OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.", FRONTIERS IN ONCOLOGY, vol. 5, no. 34, 16 February 2015 (2015-02-16), pages 1 - 14, XP055326958, DOI: 10.3389/fonc.2015.00034 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MA43389A (en) | 2021-05-12 |
| WO2017096281A1 (en) | 2017-06-08 |
| EP3383914A1 (en) | 2018-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR24C1044I2 (en) | ANTI-C5 ANTIBODIES AND METHODS OF USE THEREOF | |
| EP3383914A4 (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USE | |
| MA53355A (en) | ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF | |
| MA42043A (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USE THEREOF | |
| MA51552A (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USE | |
| EP3436048A4 (en) | NEOANTIGENES AND METHODS OF USE | |
| MA47849A (en) | ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE | |
| MA42447A (en) | ANTI-PD-1 ANTIBODIES, ACTIVABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF | |
| MA49950A (en) | ANTI-B7-H4 ANTIBODIES AND PROCEDURES FOR USE | |
| MA46529A (en) | ANTI-LAG-3 ANTIBODIES AND PROCESSES FOR USE | |
| MA42971A (en) | ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PLD1 ANTIBODIES, AND METHODS OF USE THEREOF | |
| MA43018A (en) | ANTI-PD1 ANTIBODIES AND METHODS OF USE | |
| MA50949A (en) | ANTI-CTLA-4 ANTIBODIES AND PROCESSES FOR USE | |
| EP3491025A4 (en) | FCRN ANTIBODIES AND METHODS OF USE | |
| EP3386536A4 (en) | ANTIBODY AGONIST-CONSTRUCT CONJUGATE CONJUGATE COMPOSITION AND METHODS OF USING THE SAME | |
| EP3472316A4 (en) | ANTI-C5 ANTIBODIES AND METHODS OF USE THEREOF | |
| EP3383430A4 (en) | ANTIBODIES AND THEIR METHODS OF USE | |
| EP3298168A4 (en) | STABILIZED REDUCING AGENTS AND METHODS OF USE | |
| EP3436476A4 (en) | ANTI-RYK ANTIBODIES AND METHODS OF USE THEREOF | |
| EP3436030A4 (en) | CHIMERIC RECEPTORS AND METHODS OF USE | |
| EP3390624A4 (en) | MODIFIED TARGETED MODIFICATION POLYPEPTIDES AND METHODS OF USE | |
| MA43658A (en) | ANTI-MMR1 ANTIBODIES, ROR1 X CD3 BISPECIFIC ANTIBODIES, AND METHODS OF USE THEREOF | |
| MA55097A (en) | OXYSTEROLS AND METHODS OF USE THEREOF | |
| EP3319612A4 (en) | OXYSTEOLS AND METHODS OF USE | |
| EP3319610A4 (en) | OXYSTEOLS AND METHODS OF USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20180629 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BREOUS-NYSTROM, EKATERINA V. Inventor name: SEIBERT, VOLKER Inventor name: MERGHOUB, TAHA Inventor name: WILSON, NICHOLAS S. Inventor name: WAIGHT, JEREMY D. Inventor name: VAN DIJK, MARC Inventor name: SCHAER, DAVID Inventor name: RITTER, GERD Inventor name: HIRSCHHORN-CYMERMAN, DANIEL |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20191002 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/28 20060101AFI20190926BHEP Ipc: G01N 33/68 20060101ALI20190926BHEP Ipc: A61K 39/395 20060101ALI20190926BHEP |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1260993 Country of ref document: HK |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20210409 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230413 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20240305 |